Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami experience

Jennifer T. Trent, Robert Kirsner, Paolo Romanelli, Francisco A. Kerdel

Research output: Contribution to journalArticle

189 Citations (Scopus)

Abstract

Background: Toxic epidermal necrolysis (TEN) is a rare, life-threatening condition caused by certain medications. Keratinocytes affected by TEN have been found to undergo apoptosis mediated by Fas-FasL interactions. Treatment with intravenous immunoglobulin (IVIG) has been proposed to inhibit this interaction. Objective: To demonstrate the effectiveness of IVIG therapy in reducing mortality in patients with TEN. Design: A retrospective analysis of 16 consecutive patients with TEN who were treated with IVIG. The SCORTEN system, a validated predictor of TEN mortality, was used to analyze the data of these patients. Using SCORTEN, we compared the predicted mortality of our patient population with observed mortality. Setting: Dermatology inpatient unit at a university-affiliated hospital. Intervention: All 16 patients received IVIG treatment daily for 4 days. Fifteen patients received 1 g/kg per day and 1 patient received 0.4 g/kg per day. Main Outcome Measures: For each patient, causes of TEN and other medical problems were documented prior to IVIG therapy, as were the 7 independent SCORTEN risk factors. Results: One patient died. Based on the SCORTEN system, 5.81 patients were expected to die. These mortality rates were compared using the standardized mortality ratio (SMR) analysis ([Σ observed deaths/Σ expected deaths] X 100) to determine the efficacy of this treatment, which showed that patients with TEN treated with IVIG were 83% less likely to die than those not treated with IVIG (SMR=0.17; 95% confidence interval, 0.0-0.96). Conclusion: Based on comparison of our observed mortality rate with the SCORTEN-predicted mortality rate, treatment with IVIG significantly decreased mortality in patients with TEN.

Original languageEnglish
Pages (from-to)39-43
Number of pages5
JournalArchives of Dermatology
Volume139
Issue number1
DOIs
StatePublished - Jan 1 2003
Externally publishedYes

Fingerprint

Stevens-Johnson Syndrome
Intravenous Immunoglobulins
Mortality
Therapeutics
Passive Immunization
Dermatology
Keratinocytes
Inpatients

ASJC Scopus subject areas

  • Dermatology

Cite this

Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN : The University of Miami experience. / Trent, Jennifer T.; Kirsner, Robert; Romanelli, Paolo; Kerdel, Francisco A.

In: Archives of Dermatology, Vol. 139, No. 1, 01.01.2003, p. 39-43.

Research output: Contribution to journalArticle

@article{100bfe48441d439bad7da3f0c44e5f41,
title = "Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami experience",
abstract = "Background: Toxic epidermal necrolysis (TEN) is a rare, life-threatening condition caused by certain medications. Keratinocytes affected by TEN have been found to undergo apoptosis mediated by Fas-FasL interactions. Treatment with intravenous immunoglobulin (IVIG) has been proposed to inhibit this interaction. Objective: To demonstrate the effectiveness of IVIG therapy in reducing mortality in patients with TEN. Design: A retrospective analysis of 16 consecutive patients with TEN who were treated with IVIG. The SCORTEN system, a validated predictor of TEN mortality, was used to analyze the data of these patients. Using SCORTEN, we compared the predicted mortality of our patient population with observed mortality. Setting: Dermatology inpatient unit at a university-affiliated hospital. Intervention: All 16 patients received IVIG treatment daily for 4 days. Fifteen patients received 1 g/kg per day and 1 patient received 0.4 g/kg per day. Main Outcome Measures: For each patient, causes of TEN and other medical problems were documented prior to IVIG therapy, as were the 7 independent SCORTEN risk factors. Results: One patient died. Based on the SCORTEN system, 5.81 patients were expected to die. These mortality rates were compared using the standardized mortality ratio (SMR) analysis ([Σ observed deaths/Σ expected deaths] X 100) to determine the efficacy of this treatment, which showed that patients with TEN treated with IVIG were 83{\%} less likely to die than those not treated with IVIG (SMR=0.17; 95{\%} confidence interval, 0.0-0.96). Conclusion: Based on comparison of our observed mortality rate with the SCORTEN-predicted mortality rate, treatment with IVIG significantly decreased mortality in patients with TEN.",
author = "Trent, {Jennifer T.} and Robert Kirsner and Paolo Romanelli and Kerdel, {Francisco A.}",
year = "2003",
month = "1",
day = "1",
doi = "10.1001/archderm.139.1.39",
language = "English",
volume = "139",
pages = "39--43",
journal = "JAMA Dermatology",
issn = "2168-6068",
publisher = "American Medical Association",
number = "1",

}

TY - JOUR

T1 - Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN

T2 - The University of Miami experience

AU - Trent, Jennifer T.

AU - Kirsner, Robert

AU - Romanelli, Paolo

AU - Kerdel, Francisco A.

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Background: Toxic epidermal necrolysis (TEN) is a rare, life-threatening condition caused by certain medications. Keratinocytes affected by TEN have been found to undergo apoptosis mediated by Fas-FasL interactions. Treatment with intravenous immunoglobulin (IVIG) has been proposed to inhibit this interaction. Objective: To demonstrate the effectiveness of IVIG therapy in reducing mortality in patients with TEN. Design: A retrospective analysis of 16 consecutive patients with TEN who were treated with IVIG. The SCORTEN system, a validated predictor of TEN mortality, was used to analyze the data of these patients. Using SCORTEN, we compared the predicted mortality of our patient population with observed mortality. Setting: Dermatology inpatient unit at a university-affiliated hospital. Intervention: All 16 patients received IVIG treatment daily for 4 days. Fifteen patients received 1 g/kg per day and 1 patient received 0.4 g/kg per day. Main Outcome Measures: For each patient, causes of TEN and other medical problems were documented prior to IVIG therapy, as were the 7 independent SCORTEN risk factors. Results: One patient died. Based on the SCORTEN system, 5.81 patients were expected to die. These mortality rates were compared using the standardized mortality ratio (SMR) analysis ([Σ observed deaths/Σ expected deaths] X 100) to determine the efficacy of this treatment, which showed that patients with TEN treated with IVIG were 83% less likely to die than those not treated with IVIG (SMR=0.17; 95% confidence interval, 0.0-0.96). Conclusion: Based on comparison of our observed mortality rate with the SCORTEN-predicted mortality rate, treatment with IVIG significantly decreased mortality in patients with TEN.

AB - Background: Toxic epidermal necrolysis (TEN) is a rare, life-threatening condition caused by certain medications. Keratinocytes affected by TEN have been found to undergo apoptosis mediated by Fas-FasL interactions. Treatment with intravenous immunoglobulin (IVIG) has been proposed to inhibit this interaction. Objective: To demonstrate the effectiveness of IVIG therapy in reducing mortality in patients with TEN. Design: A retrospective analysis of 16 consecutive patients with TEN who were treated with IVIG. The SCORTEN system, a validated predictor of TEN mortality, was used to analyze the data of these patients. Using SCORTEN, we compared the predicted mortality of our patient population with observed mortality. Setting: Dermatology inpatient unit at a university-affiliated hospital. Intervention: All 16 patients received IVIG treatment daily for 4 days. Fifteen patients received 1 g/kg per day and 1 patient received 0.4 g/kg per day. Main Outcome Measures: For each patient, causes of TEN and other medical problems were documented prior to IVIG therapy, as were the 7 independent SCORTEN risk factors. Results: One patient died. Based on the SCORTEN system, 5.81 patients were expected to die. These mortality rates were compared using the standardized mortality ratio (SMR) analysis ([Σ observed deaths/Σ expected deaths] X 100) to determine the efficacy of this treatment, which showed that patients with TEN treated with IVIG were 83% less likely to die than those not treated with IVIG (SMR=0.17; 95% confidence interval, 0.0-0.96). Conclusion: Based on comparison of our observed mortality rate with the SCORTEN-predicted mortality rate, treatment with IVIG significantly decreased mortality in patients with TEN.

UR - http://www.scopus.com/inward/record.url?scp=0037231873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037231873&partnerID=8YFLogxK

U2 - 10.1001/archderm.139.1.39

DO - 10.1001/archderm.139.1.39

M3 - Article

C2 - 12533162

AN - SCOPUS:0037231873

VL - 139

SP - 39

EP - 43

JO - JAMA Dermatology

JF - JAMA Dermatology

SN - 2168-6068

IS - 1

ER -